新型口服抗凝剂：接受内镜检查患者的实际管理
The new oral anticoagulants: practical management for patients attending for endoscopic procedures.
作者信息
Woodhouse C, Evans G, Muller A F
机构信息
Department of Gastroenterology, The Kent and Canterbury Hospital, Canterbury, Kent, UK.
Department of Haemophilia, The Kent and Canterbury Hospital, Canterbury, Kent, UK.
出版信息
Frontline Gastroenterol. 2013 Jul;4(3):213-218. doi: 10.1136/flgastro-2013-100325. Epub 2013 Apr 11.
Abstract
Guidelines published by the British Society of Gastroenterology have standardised the care of patients attending for endoscopy procedures, taking aspirin, clopidogrel and warfarin. Two new oral anticoagulant drugs, Rivaroxaban and Dabigatran, are licensed and National Institute of Clinical Excellence (NICE) approved for use in the UK. Unlike warfarin, these drugs do not require regular monitoring, and are at least as effective in preventing stroke in non-valvular atrial fibrillation. As such, they are likely to become popular among patients and clinicians alike. This paper summarises the practical management of patients taking these drugs attending for endoscopic procedures.
摘要
英国胃肠病学会发布的指南规范了接受内窥镜检查、正在服用阿司匹林、氯吡格雷和华法林的患者的护理。两种新型口服抗凝药物利伐沙班和达比加群已在英国获得许可并经国家临床优化研究所（NICE）批准使用。与华法林不同，这些药物不需要定期监测，并且在预防非瓣膜性心房颤动的中风方面至少同样有效。因此，它们可能会在患者和临床医生中都受到欢迎。本文总结了服用这些药物的患者接受内窥镜检查的实际管理方法。
相似文献
1
The new oral anticoagulants: practical management for patients attending for endoscopic procedures.新型口服抗凝剂：接受内镜检查患者的实际管理
Frontline Gastroenterol. 2013 Jul;4(3):213-218. doi: 10.1136/flgastro-2013-100325. Epub 2013 Apr 11.
2
3
Consideration of clinical variables for choosing new anticoagulant alternatives to warfarin for the management of non-valvular atrial fibrillation.在非瓣膜性心房颤动管理中选择新型抗凝药物替代华法林时临床变量的考量。
J Clin Pharm Ther. 2014 Dec;39(6):628-36. doi: 10.1111/jcpt.12207. Epub 2014 Sep 24.
4
Sex-Specific Comparative Effectiveness of Oral Anticoagulants in Elderly Patients With Newly Diagnosed Atrial Fibrillation.口服抗凝剂在新诊断房颤老年患者中的性别特异性比较疗效
Circ Cardiovasc Qual Outcomes. 2017 Apr;10(4). doi: 10.1161/CIRCOUTCOMES.116.003418.
5
Comparison of the cost-effectiveness of new oral anticoagulants for the prevention of stroke and systemic embolism in atrial fibrillation in a UK setting.英国背景下新型口服抗凝剂预防心房颤动患者中风和全身性栓塞的成本效益比较。
Clin Ther. 2014 Dec 1;36(12):2015-2028.e2. doi: 10.1016/j.clinthera.2014.09.015. Epub 2014 Oct 23.
6
Persistence and outcomes of non-vitamin K antagonist oral anticoagulants versus warfarin in patients with non-valvular atrial fibrillation.非维生素K拮抗剂类口服抗凝药与华法林在非瓣膜性心房颤动患者中的疗效持久性及转归
J Clin Nurs. 2019 May;28(9-10):1839-1846. doi: 10.1111/jocn.14797. Epub 2019 Feb 12.
7
Stroke prevention in patients with atrial fibrillation in France: comparative cost-effectiveness of new oral anticoagulants (apixaban, dabigatran, and rivaroxaban), warfarin, and aspirin.法国心房颤动患者的卒中预防：新型口服抗凝剂（阿哌沙班、达比加群和利伐沙班）、华法林和阿司匹林的成本效果比较。
J Med Econ. 2014 Aug;17(8):587-98. doi: 10.3111/13696998.2014.923891. Epub 2014 May 29.
8
Major Bleeding Complications and Persistence With Oral Anticoagulation in Non-Valvular Atrial Fibrillation: Contemporary Findings in Real-Life Danish Patients.非瓣膜性心房颤动患者的大出血并发症与口服抗凝治疗的持续性：丹麦真实患者的当代研究结果
J Am Heart Assoc. 2017 Feb 14;6(2):e004517. doi: 10.1161/JAHA.116.004517.
9
Treatment Persistence and Discontinuation with Rivaroxaban, Dabigatran, and Warfarin for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation in the United States.在美国，利伐沙班、达比加群和华法林用于非瓣膜性心房颤动患者预防卒中的治疗持续性和停药情况。
PLoS One. 2016 Jun 21;11(6):e0157769. doi: 10.1371/journal.pone.0157769. eCollection 2016.
10
Effectiveness and Safety of Anticoagulants in Adults with Non-valvular Atrial Fibrillation and Concomitant Coronary/Peripheral Artery Disease.非瓣膜性心房颤动合并冠状动脉/外周动脉疾病成人患者抗凝治疗的有效性和安全性。
Am J Med. 2018 Sep;131(9):1075-1085.e4. doi: 10.1016/j.amjmed.2018.05.007. Epub 2018 May 26.
引用本文的文献
1
The new oral anticoagulants: new uncertainties for endoscopists.新型口服抗凝剂：给内镜医师带来的新的不确定性。
Frontline Gastroenterol. 2013 Jul;4(3):164-165. doi: 10.1136/flgastro-2013-100326. Epub 2013 May 30.
2
Acute upper gastrointestinal bleeding.急性上消化道出血
Clin Med (Lond). 2015 Oct;15(5):481-5. doi: 10.7861/clinmedicine.15-5-481.
3
British Society of Gastroenterology/Association of Coloproctologists of Great Britain and Ireland guidelines for the management of large non-pedunculated colorectal polyps.英国胃肠病学会/大不列颠及爱尔兰结直肠外科学会关于大型无蒂结直肠息肉管理的指南
Gut. 2015 Dec;64(12):1847-73. doi: 10.1136/gutjnl-2015-309576. Epub 2015 Jun 23.
本文引用的文献
1
Guideline on the management of bleeding in patients on antithrombotic agents.抗血栓药物治疗患者出血管理指南
Br J Haematol. 2013 Jan;160(1):35-46. doi: 10.1111/bjh.12107. Epub 2012 Nov 1.
2
Analysis of upper gastrointestinal adverse events among patients given dabigatran in the RE-LY trial.RE-LY 试验中接受达比加群治疗的患者上消化道不良事件分析。
Clin Gastroenterol Hepatol. 2013 Mar;11(3):246-52.e1-5. doi: 10.1016/j.cgh.2012.10.021. Epub 2012 Oct 24.
3
The use of FEIBA® in the correction of coagulation abnormalities induced by dabigatran.依达肝素治疗达比加群诱导的凝血异常
Int J Lab Hematol. 2013 Apr;35(2):222-4. doi: 10.1111/ijlh.12005. Epub 2012 Sep 28.
4
Reversal of dabigatran anticoagulation by prothrombin complex concentrate (Beriplex P/N) in a rabbit model.在兔模型中凝血酶原复合物浓缩物（Beriplex P/N）逆转达比加群抗凝作用。
J Thromb Haemost. 2012 Sep;10(9):1841-8. doi: 10.1111/j.1538-7836.2012.04859.x.
5
Anticoagulation, novel agents, and procedures: can we pardon the interruption?抗凝、新型药物与手术：我们能否原谅这种干扰？
Circulation. 2012 Jul 17;126(3):255-7. doi: 10.1161/CIRCULATIONAHA.112.115188. Epub 2012 Jun 14.
6
Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial.与华法林相比，达比加群的围手术期出血和血栓栓塞事件：来自随机评估长期抗凝治疗（RE-LY）随机试验的结果。
Circulation. 2012 Jul 17;126(3):343-8. doi: 10.1161/CIRCULATIONAHA.111.090464. Epub 2012 Jun 14.
7
How I treat with anticoagulants in 2012: new and old anticoagulants, and when and how to switch.2012 年我如何抗凝治疗：新型抗凝药和传统抗凝药，以及何时及如何转换。
Blood. 2012 Mar 29;119(13):3016-23. doi: 10.1182/blood-2011-10-378950. Epub 2012 Feb 1.
8
Reversal of anticoagulant effects of edoxaban, an oral, direct factor Xa inhibitor, with haemostatic agents.依度沙班（一种口服、直接 Xa 因子抑制剂）的抗凝作用被止血剂逆转。
Thromb Haemost. 2012 Feb;107(2):253-9. doi: 10.1160/TH11-09-0668. Epub 2011 Dec 21.
9
Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects.在健康受试者中，用凝血酶原复合物浓缩物逆转利伐沙班和达比加群：一项随机、安慰剂对照、交叉研究。
Circulation. 2011 Oct 4;124(14):1573-9. doi: 10.1161/CIRCULATIONAHA.111.029017. Epub 2011 Sep 6.
10
Apixaban versus warfarin in patients with atrial fibrillation.阿哌沙班与华法林用于房颤患者。
N Engl J Med. 2011 Sep 15;365(11):981-92. doi: 10.1056/NEJMoa1107039. Epub 2011 Aug 27.
Zotero 插件